NIH New Grant Awards Decline 63% in 2026 Amid Shift to Multiyear Forward-Funding Policy

For university researchers, lab directors, and the institutions that support them, the financial strategy for sustaining biomedical research has fundamentally changed. The actionable takeaway for the academic community is clear: laboratories must adapt to a landscape of fewer, but fully upfront-funded, federal grants. The National Institutes of Health has issued 63% fewer new research grants in the first half of fiscal year 2026, according to data from the Association of American Medical Colleges.[1]

While headlines point to a collapse in science funding, the data reveals a structural shift in how money is distributed rather than a pure budget cut. The bottleneck stems primarily from a transition to a multiyear forward-funding model mandated by the White House Office of Management and Budget. This policy fundamentally alters the cash flow of American biomedical science.[2]

Historically, the NIH budgeted research dollars year by year. When a scientist won a five-year grant, the agency sent the researcher their allotted money annually, obligating future years with funds appropriated in those respective future fiscal years. This allowed the agency to spread its annual budget across a vast number of concurrent projects.[2]

Under the new system, the NIH must obligate the entire cost of most multiyear awards in the single year they are awarded. If a lab wins a $2 million grant spread over four years, the NIH now deducts the full $2 million from its current fiscal year budget immediately.[2]

The mathematical consequence of this policy is a severe, temporary contraction in the volume of new awards. Because each new grant now consumes its full multiyear budget upfront, there is significantly less money available to fund new projects in the current cycle. Analysis indicates this policy alone is projected to eliminate roughly 970 competing grants in FY 2026.

The funding slowdown was exacerbated by administrative hurdles. A 43-day government shutdown in the fall consumed weeks of processing time, and the OMB restricted NIH spending authority for nearly half the fiscal year, releasing the hold only in mid-March.

Furthermore, a new requirement that every Notice of Funding Opportunity clear political appointees at the NIH, the Department of Health and Human Services, and the OMB has slowed the pipeline to a trickle. Just 14 NOFOs were published through mid-March, compared with 756 across all of 2024.

The data shows that early-stage investigators are bearing the brunt of the transition. Success rates for researchers seeking their first R01-equivalent grant—the standard independent research award—have plummeted as the pool of available funds for new projects shrinks.

Overall, only 17% of research-grant applicants received an NIH award in the most recent cycle, marking the lowest success rate in 30 years. At specific institutes that adopted the forward-funding policy early, such as the National Cancer Institute, success rates have cratered from one in 10 to one in 25.[2]

AI

The evidence regarding the long-term impact remains thin, but analysts warn of a severe human capital erosion loop. Reduced funding for training and salaries could drive researchers out of the field, resulting in lost jobs and an accelerated ceding of scientific leadership to other countries.[2]

There is no replacing the NIH as the central funder of American biomedical research; private foundations, industry, and philanthropy do not have the capacity to fill a gap of this magnitude. High-risk, long-horizon basic science lacks the short-term returns that private markets demand.[2]

While the transition is causing immediate friction, the NIH-funded research community is being urged to adapt to a reality of significantly reduced new awards for a period of two to three years. Institutions that successfully navigate this bottleneck will be those that adjust their financial planning to account for the upfront funding model and prioritize retaining early-career talent through the transition.[2]